Adoke Yeka1, Ruth Kigozi2, Melissa D Conrad3, Myers Lugemwa4, Peter Okui4, Charles Katureebe5, Kassahun Belay6, Bryan K Kapella7, Michelle A Chang8, Moses R Kamya9, Sarah G Staedke10, Grant Dorsey3, Philip J Rosenthal3. 1. School of Public Health, Makerere University College of Health Sciences Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda. 2. Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda. 3. Department of Medicine, University of California, San Francisco. 4. National Malaria Control Program, Ministry of Health, President's Malaria Initiative, Kampala, Uganda. 5. World Health Organization, President's Malaria Initiative, Kampala, Uganda. 6. US Agency for International Development, President's Malaria Initiative, Kampala, Uganda. 7. Centers for Disease Control and Prevention (CDC), President's Malaria Initiative, Kampala, Uganda. 8. Malaria Branch, Division of Parasitic Diseases and Malaria, CDC, Atlanta, Georgia. 9. Department of Medicine, Makerere University College of Health Sciences Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda. 10. Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda London School of Hygiene and Tropical Medicine, United Kingdom.
Abstract
BACKGROUND: In treating malaria in Uganda, artemether-lumefantrine (AL) has been associated with a lower risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ), but changing treatment practices may have altered parasite susceptibility. METHODS: We enrolled 602 children aged 6-59 months with uncomplicated falciparum malaria from 3 health centers in 2013-2014 and randomly assigned them to receive treatment with AS/AQ or AL. Primary outcomes were risks of recurrent parasitemia within 28 days, with or without adjustment to distinguish recrudescence from new infection. Drug safety and tolerability and Plasmodium falciparum resistance-mediating polymorphisms were assessed. RESULTS: Of enrolled patients, 594 (98.7%) completed the 28-day study. Risks of recurrent parasitemia were lower with AS/AQ at all 3 sites (overall, 28.6% vs 44.6%; P < .001). Recrudescences were uncommon, and all occurred after AL treatment (0% vs 2.5%; P = .006). Recovery of the hemoglobin level was greater with AS/AQ (1.73 vs 1.39 g/dL; P = .04). Both regimens were well tolerated; serious adverse events were uncommon (1.7% in the AS/AQ group and 1.0% in the AL group). AS/AQ selected for mutant pfcrt/pfmdr1 polymorphisms and AL for wild-type pfcrt/pfmdr1 polymorphisms associated with altered drug susceptibility. CONCLUSIONS: AS/AQ treatment was followed by fewer recurrences than AL treatment, contrasting with older data. Each regimen selected for polymorphisms associated with decreased treatment response. Research should consider multiple or rotating regimens to maintain treatment efficacies.
BACKGROUND: In treating malaria in Uganda, artemether-lumefantrine (AL) has been associated with a lower risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ), but changing treatment practices may have altered parasite susceptibility. METHODS: We enrolled 602 children aged 6-59 months with uncomplicated falciparum malaria from 3 health centers in 2013-2014 and randomly assigned them to receive treatment with AS/AQ or AL. Primary outcomes were risks of recurrent parasitemia within 28 days, with or without adjustment to distinguish recrudescence from new infection. Drug safety and tolerability and Plasmodium falciparum resistance-mediating polymorphisms were assessed. RESULTS: Of enrolled patients, 594 (98.7%) completed the 28-day study. Risks of recurrent parasitemia were lower with AS/AQ at all 3 sites (overall, 28.6% vs 44.6%; P < .001). Recrudescences were uncommon, and all occurred after AL treatment (0% vs 2.5%; P = .006). Recovery of the hemoglobin level was greater with AS/AQ (1.73 vs 1.39 g/dL; P = .04). Both regimens were well tolerated; serious adverse events were uncommon (1.7% in the AS/AQ group and 1.0% in the AL group). AS/AQ selected for mutant pfcrt/pfmdr1 polymorphisms and AL for wild-type pfcrt/pfmdr1 polymorphisms associated with altered drug susceptibility. CONCLUSIONS: AS/AQ treatment was followed by fewer recurrences than AL treatment, contrasting with older data. Each regimen selected for polymorphisms associated with decreased treatment response. Research should consider multiple or rotating regimens to maintain treatment efficacies.
Authors: Samuel L Nsobya; Christian Dokomajilar; Moses Joloba; Grant Dorsey; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2007-06-11 Impact factor: 5.191
Authors: Roland A Cooper; Melissa D Conrad; Quentin D Watson; Stephanie J Huezo; Harriet Ninsiima; Patrick Tumwebaze; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-06-01 Impact factor: 5.191
Authors: Babacar Faye; André Touré Offianan; Jean Louis Ndiaye; Roger Clement Tine; Walatchin Touré; Kali Djoman; Khadime Sylla; Paulette Suzanne Ndiaye; Louis Penali; Oumar Gaye Journal: Trop Med Int Health Date: 2010-03-01 Impact factor: 2.622
Authors: Maxwell Kilama; David L Smith; Robert Hutchinson; Ruth Kigozi; Adoke Yeka; Geoff Lavoy; Moses R Kamya; Sarah G Staedke; Martin J Donnelly; Chris Drakeley; Bryan Greenhouse; Grant Dorsey; Steve W Lindsay Journal: Malar J Date: 2014-03-21 Impact factor: 2.979
Authors: Melissa D Conrad; Victor Bigira; James Kapisi; Mary Muhindo; Moses R Kamya; Diane V Havlir; Grant Dorsey; Philip J Rosenthal Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240
Authors: Adoke Yeka; Grant Dorsey; Moses R Kamya; Ambrose Talisuna; Myers Lugemwa; John Bosco Rwakimari; Sarah G Staedke; Philip J Rosenthal; Fred Wabwire-Mangen; Hasifa Bukirwa Journal: PLoS One Date: 2008-06-11 Impact factor: 3.240
Authors: Patrick Tumwebaze; Stephen Tukwasibwe; Aimee Taylor; Melissa Conrad; Emmanuel Ruhamyankaka; Victor Asua; Andrew Walakira; Joaniter Nankabirwa; Adoke Yeka; Sarah G Staedke; Bryan Greenhouse; Samuel L Nsobya; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: J Infect Dis Date: 2017-02-15 Impact factor: 5.226
Authors: Joaniter I Nankabirwa; Melissa D Conrad; Jennifer Legac; Stephen Tukwasibwe; Patrick Tumwebaze; Bonnie Wandera; Simon J Brooker; Sarah G Staedke; Moses R Kamya; Sam L Nsobya; Grant Dorsey; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Stephanie A Rasmussen; Frida G Ceja; Melissa D Conrad; Patrick K Tumwebaze; Oswald Byaruhanga; Thomas Katairo; Samuel L Nsobya; Philip J Rosenthal; Roland A Cooper Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Melissa D Conrad; Daniel Mota; Alex Musiime; Maxwell Kilama; John Rek; Moses Kamya; Grant Dorsey; Philip J Rosenthal Journal: Am J Trop Med Hyg Date: 2017-10-10 Impact factor: 2.345
Authors: Melissa D Conrad; Daniel Mota; Marissa Foster; Stephen Tukwasibwe; Jennifer Legac; Patrick Tumwebaze; Meghan Whalen; Abel Kakuru; Patience Nayebare; Erika Wallender; Diane V Havlir; Prasanna Jagannathan; Liusheng Huang; Francesca Aweeka; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: J Infect Dis Date: 2017-11-15 Impact factor: 5.226